Very salient point eyes.
IMO, when Mesoblast has Remestemcel-L approved by the most powerful body in the world, the FDA, for use on patients with the final fatal stage of COVID-19, ARDS, the noise around the share price will die off as the market cap moves from AU$1B to multiple AU$10B's and Mesoblast will be confronted with some tough decisions regarding supply of it's Stem Cells as other jurisdictions seek out Mesoblast and apply for our MSC's.
IMO, it is a foregone conclusion that Mesoblast have been engaged very closely with Lonza since the outbreak and have developed multiple mass manufacturing plans ready to "push the button".
GLTAH
Cell Therapy News/Articles, page-1347
-
- There are more pages in this discussion • 16,480 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |